Efficacy of Continuous, Daily, Oral, Ultra-low-dose 200 mg Acyclovir to Prevent Herpes Zoster Events Among Bortezomib-treated Patients: A Report From Retrospective Study - Concepedia

Concepedia

Publication | Open Access

Efficacy of Continuous, Daily, Oral, Ultra-low-dose 200 mg Acyclovir to Prevent Herpes Zoster Events Among Bortezomib-treated Patients: A Report From Retrospective Study

DOI Full Paper Access

20

Citations

19

References

2011

Year

Tomohiro Aoki, Takeshi Nishiyama, Nobuhiko Imahashi, K Kitamura

Japanese Journal of Clinical Oncology

Abstract

Continuous prophylaxis by oral 200 mg/day acyclovir in multiple myeloma patients receiving bortezomib treatment is effective and sufficient in preventing herpes zoster.

References

	Year	Citations

Page 1